A founder effect for p47(phox)Trp193Ter chronic granulomatous disease in Kavkazi Jews

Martin de Boer, Shay Tzur, Karin van Leeuwen, Paula C. D. Dencher, Karl Skorecki, Baruch Wolach, Ronit Gavrieli, Ivane Nasidze, Mark Stoneking, Michael W. T. Tanck, Dirk Roos

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Chronic granulomatous disease (CGD) is a rare congenital immune deficiency caused by mutations in any of the five genes encoding NADPH oxidase subunits. One of these genes is NCF1, encoding the p47(phox) protein. A group of 39 patients, 14 of whom are of Kavkazi Jewish descent, was investigated for a founder effect for the mutation c.579G>A (p.Trp193Ter) in NCF1. We analyzed various genetic markers in the NCF1 region, including two single nucleotide polymorphisms (SNPs) in NCF1 and two short tandem repeats (STRs) located near NCF1. Most patients were homozygous for the c.579G>A mutation, but three patients were hemizygotes, with a deletion of NCF1 on the other allele, and three patients were compound heterozygotes with another mutation in NCF1. All Kavkazi Jewish patients had a c.295G_c.345T SNP combination in NCF1 and shared a common number of repeats in STR3. In addition, 90% of the Kavkazi Jewish patients shared a common number of repeats in STR1. This uniformity indicates that the c.579G>A mutation in NCF1 was introduced some 1200-2300 years ago in the Kavkazi Jewish population. Variation amongst the other investigated populations from the Middle East indicates that this mutation exists in these non-Kavkazi populations already for more than 5000 years
Original languageEnglish
Pages (from-to)320-327
JournalBlood cells, molecules & diseases
Volume55
Issue number4
DOIs
Publication statusPublished - 2015

Cite this